Risk of COVID‐19 infection and seizure exacerbation among patients with epilepsy during the peak of Omicron wave

Epilepsia Open, Journal Year: 2024, Volume and Issue: 9(4), P. 1416 - 1425

Published: May 25, 2024

Abstract Objectives Existing data regarding the risk of COVID‐19 infection and its effects on seizure control in patients with epilepsy (PWE) are inconclusive. Our research aims to investigate PWE who susceptible what factors contribute exacerbation. Methods From Dec 28, 2022 Feb 19, 2023, a cross‐sectional questionnaire survey among adult was conducted. The demographics, epilepsy‐related information, COVID‐19‐related variables, outcomes after were collected. Multivariate logistic analyses performed determine associated exacerbated seizures. Results Of 1557 PWE, 829 (53.2%) infected 136 (16.4%) developed exacerbation infection. Overweight/obesity (OR 1.372, 95% CI 1.075–1.753, p = 0.011), immunocompromised 3.301, 1.093–9.974, 0.031), active 1.700, 1.378–2.097, < 0.001), antiseizure medication (ASM) polytherapy 1.314, 1.065–1.621, 0.011) Active 4.696, 2.568–8.586, 0.001) fever‐associated seizures 4.298, 95%CI 2.659–6.946, Significance overweight/obesity, immunocompromised, epilepsy, ASM at higher Once COVID‐19, Plain language summary Patients do not appear be more than general population. 16.4% had have experienced within past 12 months before tend contract often, likely experience exacerbations following

Language: Английский

A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 12, 2024

To investigate the trends in epilepsy prevalence, incidence, mortality, and disability-adjusted life-years (DALYs) all ages, with risk factors for - associated death, from 1990 to 2021.

Language: Английский